Osteopontin/OPN Antibody (190312) [Alexa Fluor® 647]

• Reactivity: Hu
• Applications: IHC
• Clone: 190312
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Alexa Fluor 647

Osteopontin/OPN Antibody (190312) [Alexa Fluor® 647] Summary

• Immunogen: Mouse myeloma cell line NS0-derived recombinant human Osteopontin
  Ile17-Asn300
  Accession # NP_000573.1
• Specificity: Detects human Osteopontin in direct ELISAs.
• Isotype: IgG2b
• Clonality: Monoclonal
• Host: Mouse
• Purity Statement: Protein A or G purified

Applications/Dilutions

• Dilutions:
  • Immunohistochemistry

Packaging, Storage & Formulations

• Storage: Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied
• Buffer: Supplied 0.2mg/ml in 1X PBS with RDF1 and 0.09% Sodium Azide

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Osteopontin/OPN Antibody (190312) [Alexa Fluor® 647]

• BNSP
• Bone sialoprotein 1
• Eta-1
• MGC110940
• Nephropontin
• OPN
• Osteopontin
• secreted phosphoprotein 1bone sialoprotein I, early T-lymphocyteactivation 1)
• secreted phosphoprotein-1 (osteopontin, bone sialoprotein)
• Spp1
• SPP-1
• SPP1/CALPHA1 fusion
• Urinary stone protein
• uropontin

Background

Osteopontin (OPN), previously called SPP1 (secreted phosphoprotein 1), Eta1(early T lymphocyte activation 1) or BSP (bone sialoprotein), is a secreted molecule in the SIBLING (small integrin binding ligand N-linked glycoprotein) family of noncollagenous matricellular proteins (1‑3). Human OPN is synthesized as a 317 aminoacid (aa) precursor protein with a 16 aa signal peptide and a 301 aa mature protein (3). Mature human OPN shares 64% and 62% aa sequence identity with mouse and rat OPN, respectively. OPN is highly acidic and has 26 potential Ser/Thr phosphorylation sites and a C‑terminal CD44 binding site (1‑4). Depending on tissue-specific modification by O- and N‑glycosylation, sulfation, phosphorylation and transglutamination, OPN can be detected at 45‑75 kDa (5, 6). The central region of OPN contains RGD and nonRGD binding sites for multiple integrins (3, 4). Adjacent to the RGD motif is the sequence SVVYGLR (SLAYGLR in mouse) which serves as a cryptic binding site for additional integrins: it is masked in full length OPN but is exposed following OPN cleavage by thrombin in tumors and sites of tissue injury
(6‑8). OPN can also be cleaved by MMP3, 7, 9, and 12 within the SVVYGLR motif and at sites closer to the C‑terminus (8, 9). OPN is widely expressed and is prominent in mineralized tissues. It inhibits bone mineralization and kidney stone formation, and promotes inflammation and cell adhesion and migration (1, 2, 4, 6). Its expression is up‑regulated during inflammation, obesity, atherosclerosis, cancer, and tissue damage, and contributes to the pathophysiology of these conditions (1, 2, 6, 9, 10).

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.